Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/14/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)

February 11, 2025 7:46 AM EST

Chardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR)

The analyst comments "The company is currently evaluating plozasiran in three other phase III studies: SHASTA-3 and SHASTA-4 in adults with SHTG (currently enrolling), and MUIR-3 in adults... More